使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and welcome to Knowles Corporation's fourth quarter and full year 2025 earnings conference call. At this time, I would like to hand the conference over to Ms. Sarah Cook. Please go ahead, Sarah.
各位大家好,歡迎參加 Knowles Corporation 2025 年第四季暨全年財報電話會議。此刻,我想將會議交給 Sarah Cook 女士。Sarah,請開始。
Sarah Cook - Vice President of Investor Relations
Sarah Cook - Vice President of Investor Relations
Thank you and welcome to our fourth quarter and full year 2025 earnings call. I'm Sarah Cook; Vice President of Investor relations, presenting with me today are Jeffrey Niew, our President and CEO; and John Anderson, our Senior Vice President and CFO.
謝謝,歡迎各位參加我們 2025 年第四季暨全年財報電話會議。我是 Sarah Cook,投資人關係副總裁;今天與我一同出席的有我們的總裁暨執行長 Jeffrey Niew,以及資深副總裁暨財務長 John Anderson。
Our call today will include remarks about future expectations, plans, and prospects for Knowles, which constitute forward-looking statements for purposes of the Safe Harbor provisions under applicable federal security laws. Forward-looking statements in this call will include comments about demand for company products, anticipated trends in company sales, expenses, and profits, and involve a number of risks and uncertainties that could cause actual results to differ materially from current expectations.
我們今天的電話會議將包含對 Knowles 未來預期、計畫與前景的評論,這些內容依適用之聯邦證券法「安全港」條款之目的構成前瞻性陳述。本次電話會議中的前瞻性陳述將包括對公司產品需求、公司銷售、費用與獲利之預期趨勢等評論,並涉及多項風險與不確定性,可能導致實際結果與目前預期出現重大差異。
The company urges investors to review the risks and uncertainties in the company's SEC filings, including but not limited to the annual report on Form 10-K for the fiscal year ended December 30, 2024, periodic reports filed from time to time with the SEC, and the risks and uncertainties identified in today's earnings release. All forward-looking statements are made as of the date of this call, and Knowles disclaims any duty to update such statements except as required by law.
公司敦促投資人檢視公司向 SEC 提交之文件中所揭露的風險與不確定性,包括但不限於截至 2024 年 12 月 30 日止會計年度之 Form 10-K 年報、公司不時向 SEC 提交之定期報告,以及今日財報新聞稿中所辨識的風險與不確定性。所有前瞻性陳述均以本次電話會議日期為準,除法律要求外,Knowles 不承擔更新該等陳述之任何義務。
In addition, pursuant to Red Ge, any non-GAAP financial measures referenced during today's conference call can be found in our press release posted on our website at knowles.com and in our current report in Form 8-K filed today with the SEC. This will include a reconciliation to the most directly comparable GAAP measure.
此外,依據 Red Ge,今日電話會議中提及的任何非 GAAP 財務衡量指標,均可在我們發布於 knowles.com 之新聞稿,以及今日向 SEC 提交的 Form 8-K 當期報告中查閱。其中將包含與最直接可比之 GAAP 指標的調節表。
All financial references on this call will be on a non-GAAP continuing operations basis with the exception of cash from operations or unless otherwise indicated. We've made selected financial information available in webcast slides, which can be found in the Investor Relations section of our website.
除營運活動現金流量或另有說明外,本次電話會議中所有財務數據皆以非 GAAP 的持續營運基礎呈現。我們已在網路直播簡報投影片中提供部分財務資訊,可於本公司網站的投資人關係專區查閱。
With that, let me turn the call over to Jeff, who will provide details on our results. Jeff?
接下來,讓我把電話交給 Jeff,由他說明我們的業績細節。Jeff?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Thanks, Sarah, and thanks to all of you for joining us today. 2025 was a breakthrough year for Knowles marked by the completion of our portfolio transformation at the end of 2024 and the beginning of our journey as an industrial technology company.
謝謝你,Sarah,也感謝各位今天加入我們。2025 年對 Knowles 而言是突破性的一年,其標誌包括我們在 2024 年底完成投資組合轉型,以及我們作為一家工業科技公司旅程的開始。
Our organic growth in 2025 exceeded our Investor Day expectations and demonstrates our strategy of leveraging our unique technologies to design custom engineered solutions and then deliver them at scale for blue chip customers and high growth markets that value our solutions. Before I discuss this a little more in detail, let me cover our Q4 2025 results.
我們 2025 年的有機成長超出投資人日的預期,展現了我們的策略:運用獨特技術設計客製化工程解決方案,並以規模化方式交付給重視我們方案的藍籌客戶與高成長市場。在我更深入討論之前,先說明 2025 年第四季的業績。
Q4 was another quarter of strong financial performance. Revenue was $162 million, up 14% year over year, exceeding the high end of our guided range. EPS was $0.36, up 33% year over year and above the midpoint of our guided range. Cash from operations was $47 million, also exceeding the high end of our guided range.
第四季再次展現強勁的財務表現。營收為 1.62 億美元,年增 14%,高於我們指引區間的上緣。每股盈餘(EPS)為 0.36 美元,年增 33%,且高於我們指引區間的中點。營運活動現金流量為 4,700 萬美元,同樣超出我們指引區間的上緣。
On a full year basis, revenue of $593 million, up 7% year over year and EPS was $1, up 21% compared to 2024. As I said last quarter, I believe our results continue to demonstrate that our focus on markets and products will be a significant competitive advantages that result in increased organic growth and positions us well for future growth.
以全年來看,營收為 5.93 億美元,年增 7%;EPS 為 1 美元,較 2024 年成長 21%。如同我上季所說,我認為我們的成果持續證明:聚焦於市場與產品將成為重要的競爭優勢,帶來更高的有機成長,並使我們在未來成長上具備良好定位。
Now turning to our segment results. In Q4, MedTech and Specialty Audio revenue was $73 million, up 4% year over year. Full year revenue was $264 million, up 4% from 2024, and at the high end of the organic growth target of 2% to 4% we presented at our Investor Day in May last year.
接著談各事業部門的表現。第四季 MedTech 與 Specialty Audio 營收為 7,300 萬美元,年增 4%。全年營收為 2.64 億美元,較 2024 年成長 4%,並達到我們去年 5 月投資人日所提出 2% 至 4% 有機成長目標的上緣。
In hearing health, Knowles is known for its superior technology and reliability. Our customers depend on our ability to deliver unique solutions to improve comfort of fit and performance with extremely low power. Our unique technologies coupled with strong intimacy with our customers' applications is allowing us to win next generation designs for MEMS microphones as well as balanced armature speakers.
在聽力健康領域,Knowles 以卓越的技術與可靠性著稱。客戶仰賴我們提供獨特解決方案,以在極低功耗下提升配戴舒適度與效能。我們的獨特技術結合與客戶應用的深度貼近,使我們得以贏得下一代 MEMS 麥克風以及平衡電樞喇叭的設計導入。
We also see the opportunity to increase our content of the device in next generation hearing health products. Beyond the hearing health market, we remain optimistic about the future growth opportunities within our micro solutions group that we detail at our Investor Day.
我們也看到在下一代聽力健康產品中提升單機內容價值的機會。除聽力健康市場之外,對於我們在投資人日所詳述之微型解決方案事業群的未來成長機會,我們仍保持樂觀。
In the Precision Device segment, Q4 revenue was $90 million, up 23% year over year. As channels inventory levels are now normalized and orders are matching and market demand, we saw strength across all our key end markets leading to an acceleration of revenue in the second half of the year.
在 Precision Device 事業部門,第四季營收為 9,000 萬美元,年增 23%。隨著通路庫存水位現已正常化,且訂單與市場需求相匹配,我們在所有主要終端市場均見到強勁表現,帶動下半年營收加速成長。
Full year revenue grew 10% year over year, exceeding the high end of the organic growth target of 6% to 8% we presented at our Investor Day in May last year. Within Precision Devices, as I stated earlier, we saw growth in all our end markets MedTech, defense, industrial, EV, and energy with revenue growing year over year. Let me provide a little color by end market.
全年營收年增 10%,超出我們去年 5 月投資人日所提出 6% 至 8% 有機成長目標的上緣。在 Precision Devices 之內,如我先前所述,我們在所有終端市場(MedTech、國防、工業、電動車(EV)與能源)皆呈現年增成長。我按終端市場補充一些說明。
In the MedTech market, we have new design winds ramping and repeat orders and production spanning across multiple product lines such as high performance ceramic capacitors and pulse power film capacitors. The number of medical devices being used to extend life expectancy and to ensure sustained quality of life is on the rise or custom reliability capacitors can be found in a multitude of implantable devices, medical imaging, and life extending treatments.
在 MedTech 市場,我們的新設計導入正逐步放量,並有重複訂單與量產,涵蓋多條產品線,例如高性能陶瓷電容與脈衝功率薄膜電容。用於延長壽命並確保持續生活品質的醫療裝置數量持續增加;我們的客製化高可靠度電容可見於多種植入式裝置、醫學影像,以及延長壽命的治療方案中。
Our defense business continues to be strong. As a sole source supplier on a number of key programs or volumes continue to grow. As I mentioned on our last earnings call, our capacitors and RF microwave solutions serve a wide variety of military applications spanning from radar to communications to munitions. Defense spending is increasing and shifting toward electronic warfare where our products are in high demand.
我們的國防業務持續強勁。作為多項關鍵專案的唯一來源供應商,我們的出貨量持續成長。如我在上次財報電話會議提到,我們的電容以及 RF 微波解決方案可用於多樣化的軍事應用,涵蓋從雷達、通訊到彈藥等領域。國防支出正在增加,並轉向電子戰領域,而我們的產品需求旺盛。
In the industrial markets, we have seen inventory levels normalized at our distribution partners. Our high performance ceramic film electrolytic capacitors serve a diverse set of applications from robotics to welding and induction heating in the industrial sector.
在工業市場方面,我們看到經銷合作夥伴的庫存水位已正常化。我們的高性能陶瓷、薄膜與電解電容服務多元應用,從機器人到焊接與工業領域的感應加熱。
The energy market continues to be an exciting opportunity for growth in 2026 and beyond, with our new specialty film line expected to start producing and delivering high volume pulse power capacitors late in the second quarter of this year.
能源市場在 2026 年及更長期仍是令人振奮的成長機會;我們的新型特殊薄膜產線預計將於今年第二季末開始生產並交付大批量脈衝功率電容。
On a more quantitative basis, to summarize, even with extremely strong shipments in Q4, we saw another quarter of healthy bookings with a book-to-bill greater than 1 in our Precision Devices segment. Our continued collaboration with our customers have led to a robust pipeline of new design wins as our customers continue to choose our innovative and differentiated solutions.
以更量化的角度總結,即使第四季出貨極為強勁,我們在 Precision Devices 事業部門仍看到另一季健康的接單表現,出貨比(book-to-bill)大於 1。我們與客戶持續協作,帶來強勁的新設計導入管線,因為客戶持續選擇我們具創新性且差異化的解決方案。
This coupled with strong secular growth trends in the markets reserve gives me confidence in our ability to continue to grow revenue throughout 2026 and beyond. Across the company we are leveraging our unique technologies, creating custom products through our customer application intimacy, and then scaling into production with our world-class operational capabilities for end markets with strong secular growth trends.
再加上我們所服務市場的強勁長期結構性成長趨勢,使我對我們在 2026 年及更長期持續提升營收的能力充滿信心。在全公司層面,我們正運用獨特技術,透過對客戶應用的深度貼近打造客製化產品,並憑藉世界級的營運能力將其規模化量產,服務具強勁長期結構性成長趨勢的終端市場。
Our 2025 results demonstrate this is a winning combination, leading to revenue and EPS growth on a year over year basis. I would like to reiterate what I previously said, I'm excited about the momentum and strength of our business. We have entered 2026 positioned well for continued strong organic revenue growth above historic levels.
我們 2025 年的成果證明這是一個成功的組合,帶動營收與 EPS 的年增成長。我想重申我先前所說的:我對我們業務的動能與強度感到振奮。我們已在 2026 年以良好態勢起步,具備持續強勁的有機營收成長動能,並高於歷史水準。
Well, the first quarter of the year is typically seasonally low. I expect to see strong year-over-year growth in the third quarter. New design wins are ramping. We have a very healthy backlog of existing orders, and we are seeing increased demand for our products. Our organic growth and increasing EBITDA continues to produce robust cash generation, resulting in a very strong balance sheet, which will allow us to pursue synergistic acquisitions and continue to buy back shares while keeping our debt at very manageable levels.
嗯,一年中的第一季通常在季節性上較為低迷。我預期第三季將看到強勁的年對年成長。新的設計案得標正在加速放量。我們既有訂單的在手訂單量非常健康,同時也看到對我們產品的需求增加。我們的有機成長與EBITDA提升持續帶來強勁的現金創造能力,形成非常強健的資產負債表,這將使我們能夠追求具協同效益的併購,並在將負債維持在非常可控水準的同時,持續回購股票。
To close, we are laser focused on what we do best, designing custom engineered products and delivering them at scale for customers and markets that value our solutions, positioning as well for growth in 2026 and beyond.
最後,我們高度聚焦於我們最擅長的事:設計客製化的工程產品,並以規模化方式交付給重視我們解決方案的客戶與市場,同時也為2026年及之後的成長做好布局。
Now let me turn the call over to John to detail our financial results and provide our Q1 guidance.
現在我把電話交給John,請他說明我們的財務結果並提供第一季指引。
John Anderson - Chief Financial Officer, Senior Vice President
John Anderson - Chief Financial Officer, Senior Vice President
Thanks, Jeff. We reported fourth quarter revenues of $162 million, up 14% from the year ago period and above the high end of our guidance range. EPFs was $0.36 in the quarter, up $0.09 or 33% from the year ago period and above the midpoint of our guidance range. Cash generated by operating activities was $47 million, also above the high end of our guidance range, driven by both increased EBITDA and lower than expected networking capital.
謝謝,Jeff。我們公布第四季營收為1.62億美元,較去年同期成長14%,並高於我們指引區間的上緣。本季EPFs為0.36美元,較去年同期增加0.09美元或成長33%,並高於我們指引區間的中點。營運活動所產生的現金為4,700萬美元,同樣高於我們指引區間的上緣,主要受惠於EBITDA增加以及營運資金低於預期。
In the Medtech and Specialty Audio segment, Q4 revenue was $73 million, up 4% compared with a year ago period, driven by increased shipment volume. On a full year basis, revenue increased by 4% over prior year levels due primarily to growth in Specialty Audio and an increase in shipment volume of stamped metal cans. Q4 gross margins were 51.9%, up slightly from the year ago period. As expected, segment gross margins for a full year of 2025 were above 50%.
在醫療科技與專業音訊(Medtech and Specialty Audio)部門,第四季營收為7,300萬美元,較去年同期成長4%,主要由出貨量增加所帶動。以全年來看,營收較前一年成長4%,主要來自專業音訊的成長以及沖壓金屬罐出貨量增加。第四季毛利率為51.9%,較去年同期小幅上升。如預期,2025年全年該部門毛利率高於50%。
The Precision Devices segment delivered fourth quarter revenues of $90 million, up 23% from the year ago period. On a full year basis, revenue increased by 10% over prior year levels, driven by strength across all our end markets and product lines. Revenue accelerated throughout the back half of the year as inventory levels normalized at our distribution partners.
精密裝置(Precision Devices)部門第四季營收為9,000萬美元,較去年同期成長23%。以全年來看,營收較前一年成長10%,主要受惠於我們所有終端市場與產品線的強勁表現。隨著通路夥伴的庫存水位恢復正常,營收在下半年持續加速。
Segment gross margins were 40.1%, up 230 basis points from the fourth quarter of 2024 as higher end market demand and production volumes in ceramic capacitors and RF microwave product lines resulted in increased factory capacity utilization. This was partially offset by higher scrap cost and production inefficiencies in connection with our specialty filmed line.
部門毛利率為40.1%,較2024年第四季提升230個基點,原因是陶瓷電容與RF微波產品線的終端市場需求與產量提高,帶動工廠產能利用率上升。但部分被較高的報廢成本以及與我們專業薄膜產線相關的生產效率不佳所抵銷。
For the full year, segment gross margins improved 140 basis points from 2024 levels despite headwinds from our specialty film line. We experienced production volume increases in RF microwave products and ceramic capacitors driving the gross margin improvement. I'm confident in our ability to continue to improve segment margins further in '26 as capacity utilization increases and efficiencies in connection with our specialty film line are realized.
全年來看,儘管專業薄膜產線帶來逆風,部門毛利率仍較2024年水準改善140個基點。我們在RF微波產品與陶瓷電容的產量增加,推動毛利率改善。我有信心在26年隨著產能利用率提升,以及專業薄膜產線相關效率改善逐步實現,我們能持續進一步提升部門毛利率。
On a total company basis, R&D expense in the quarter was $9 million, flat with Q4 2024 levels. SG&A expenses were $27 million, up $2 million from prior levels driven primarily by higher incentive compensation costs. Interest expense was $2 million and down $2 million from a year ago period as we continue to use cash generated by operations to reduce our debt levels.
以公司整體來看,本季研發費用為900萬美元,與2024年第四季持平。銷售、一般及行政(SG&A)費用為2,700萬美元,較先前水準增加200萬美元,主要由較高的激勵性薪酬成本所致。利息費用為200萬美元,較去年同期減少200萬美元,因為我們持續運用營運所產生的現金降低負債水位。
Now I'll turn to our balance sheet and cash flow. In the fourth quarter we generated $47 million in cash from operating activities and capital spending was $15 million. During the fourth quarter we repurchased 451,000 shares at a total cost of $10 million. We exited the quarter with cash of $54 million and $114 million of borrowings under our revolving credit facility.
接著我說明資產負債表與現金流。第四季我們由營運活動產生4,700萬美元現金,資本支出為1,500萬美元。第四季期間我們回購451,000股,總成本為1,000萬美元。本季末現金為5,400萬美元,循環信用額度項下借款為1.14億美元。
Lastly, our net leverage ratio based on trailing 12 months adjusted EBITDA was 0.4 times, and we have liquidity of more than $340 million as measured by cash plus unused capacity under our revolving credit facility.
最後,以過去12個月調整後EBITDA計算的淨槓桿比率為0.4倍;以現金加上循環信用額度未動用額度衡量,我們的流動性超過3.4億美元。
Before turning to Q1 guidance, I want to briefly highlight our performance relative to our full year 2025 outlook and five-year targets that we provided at our May 2025 Analyst Day. Full year revenue was $593 million and up 7% versus 2024, which was above the high end of our outlook of $560 million to $590 million. Revenues exceeded the high end of our organic growth target of 4% to 6%.
在進入第一季指引之前,我想簡要強調我們相對於2025年全年展望,以及我們在2025年5月分析師日所提供的五年目標之表現。全年營收為5.93億美元,較2024年成長7%,高於我們展望區間5.60億至5.90億美元的上緣。營收也超過我們4%至6%的有機成長目標上緣。
From a segment perspective, MedTech and Specialty Audio revenue grew by 4%, and Precision Device revenue grew by 10%, with full segments meeting or exceeding the organic revenue growth targets of 2% to 4% and 6% to 8% respectively. Adjusted EBITDA from continuing operations was $140 million, up 9% from 2024, driven by higher gross profit margins and increasing operating leverage and within the outlook range we provided. Cash from operations was $114 million or 19.2% of revenues above the midpoint of our full year outlook.
從部門角度來看,醫療科技與專業音訊營收成長4%,精密裝置營收成長10%,兩個部門皆達成或超越各自2%至4%與6%至8%的有機營收成長目標。持續營運的調整後EBITDA為1.40億美元,較2024年成長9%,主要由較高的毛利率與營運槓桿提升所帶動,且落在我們提供的展望區間內。營運現金流為1.14億美元,約占營收的19.2%,高於我們全年展望的中點。
Moving to our Q1 guidance. For the first quarter of 2026, revenues are expected to be between $143 million and $153 million, up 12% year over year at the midpoint. R&D expenses are expected to be between $9 million and $11 million. Selling and administrative expenses are expected to be within the range of $25 million to $27 million. We're projecting adjusted [EBIT] margin for the quarter to be within the range of 18% to 20%.
接著談第一季指引。2026年第一季,預期營收介於1.43億至1.53億美元,以中點計算年對年成長12%。研發費用預期介於900萬至1,100萬美元。銷售與行政費用預期落在2,500萬至2,700萬美元區間。我們預估本季調整後[EBIT]利潤率將落在18%至20%區間。
Interest expense in Q1 is estimated at $2 million, and we expect an effective tax rate of 15% to 19%. We're projecting EPS to be within a range of $0.22 to $0.26 per share, up $0.06 or 33% year to year at the midpoint. This assumes weighted average shares outstanding during a quarter of $88 million on a fully diluted basis.
第一季利息費用估計為200萬美元,我們預期有效稅率為15%至19%。我們預估EPS將落在每股0.22至0.26美元區間,以中點計算年對年增加0.06美元或成長33%。此假設本季完全稀釋後的加權平均流通股數為8,800萬股。
We're projecting cash from operating activities to be within the range of negative $5 million to $5 million. Capital spending is expected to be $10 million. We expect full year capital spending to be approximately 4% to 5% of revenues as we continue investments associated with capacity expansion related to the large energy order we received in 2025.
我們預估營運活動現金流將落在負500萬至正500萬美元區間。資本支出預期為1,000萬美元。我們預期全年資本支出約為營收的4%至5%,因我們持續進行與產能擴充相關的投資,以因應我們在2025年取得的大型能源訂單。
In conclusion, we delivered strong year over year revenue, earnings, and cash flow growth in the fouth quarter and for full year 2025. As we exited the year, we have a robust backlog and increased order activity which gives me confidence in our ability to continue to achieve revenue, earnings, and cash flow growth, which is expected to drive shareholder value throughout â26 and beyond.
總結來說,我們在第四季以及2025年全年都交出強勁的年對年營收、獲利與現金流成長。在年度結束時,我們擁有強勁的在手訂單與增加的接單活動,這讓我對我們持續達成營收、獲利與現金流成長的能力充滿信心,並預期將在‘26年及之後持續推動股東價值。
I'll now turn the call back over to the operator for the Q&A portion of our call. Operator?
現在我把電話交回給接線員,進入問答環節。接線員?
Operator
Operator
(Operator Instructions) Christopher Rolland, Susquehanna.
(接線員指示) Christopher Rolland,Susquehanna。
Christopher Rolland - Analyst
Christopher Rolland - Analyst
Hi guys, thanks for the question. And yeah, I guess the large energy order and the thin film capacity products. I guess just first an update there, have you guys seen a broadening in new customers for that product? And if you could remind us on your capacity addition plans and timing of revenue and any TAM detail or something around that would be great as well. Thank you.
嗨,各位,謝謝讓我提問。嗯,是關於那筆大型能源訂單以及薄膜產能產品。我想先請你們更新一下:你們是否看到該產品的新客戶群有擴大?另外也請提醒我們你們的產能擴增計畫,以及營收認列的時程;若能提供一些TAM細節或相關資訊也會很棒。謝謝。
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
So first, on the energy order being no different than we've kind of talked about earlier last year, which we expect this to be in the neighborhood of 25 -- north of $25 million of revenue, this year and really getting going, in the back half. Well, we should have it fully ramped in Q2 and so that's a lot by the end of Q2.
首先,關於能源訂單,跟我們去年稍早談到的情況差不多沒有不同;我們預期今年這筆訂單的營收大約在 2,500 萬美元左右、甚至高於 2,500 萬美元,而且會在下半年真正開始發力。嗯,我們應該會在第二季就把產能/出貨完全拉升到位,所以到第二季末累積的量會相當可觀。
So I think you'll see more of that, a big portion of that $25 million in the back half of the year. Overall, for the specialty film line, I think we are seeing a definitely broadening of the customer base beyond some of the medical applications defib radiotherapy, downhole fracking, military applications like rail guns. There's a definite broadening of the applications.
所以我認為你會看到更多貢獻,其中很大一部分的那 2,500 萬美元會落在下半年。整體來看,就特種薄膜產品線而言,我認為我們確實看到客戶基礎正在擴大,已經不再只侷限於一些醫療應用,例如去顫器、放射治療,還包括井下壓裂、軍事應用如電磁軌道炮。應用面確實在明顯擴張。
And I think we had talked about this a few quarters ago, that overall including the energy order, our expectations we're in that, I would say, $50 million to $65 million range for revenue off this product category in 2026. I think that still holds that we're still in that range for this year. So I think what I kind of see here is, that the specialty film line including energy really has a bright future as we look toward the future, Chris.
而且我想我們在幾個季度前談過,整體來說(包含能源訂單),我們對 2026 年這個產品類別的營收預期大約在 5,000 萬到 6,500 萬美元的區間。我認為這個看法仍然成立,今年我們仍在這個區間內。所以我看到的是,包含能源在內的特種薄膜產品線,展望未來確實前景光明,Chris。
Christopher Rolland - Analyst
Christopher Rolland - Analyst
Excellent. Great. And then as we start thinking about the future, kind of what your next big hit might be. I guess first of all, do you have some prospects that you've identified organically or internally, some next kind of big hits and or are you really looking outside? You did mention acquisitions. If you could give us an update there, are you finding some high value targets here and speaking evaluation are they reasonable?
太好了。很好。接著當我們開始思考未來,也就是你們下一個可能的「爆款」會是什麼。我想先問,你們是否已經在內部/有機成長方面辨識出一些潛在的下一個大機會?還是你們更著重於外部?你確實提到了併購。如果可以請你更新一下:你們是否正在找到一些高價值的標的?就估值而言是否合理?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Yeah. I mean obviously, it's very hard to comment like specifically but you know our pipeline continues to be good on the acquisition front, but to be honest with you, our organic opportunities over the next 24 to 36 months look pretty promising. And I'll just kind of go back to beyond the energy or situation and the pulse power specialty film line. A couple other things that, we talked about on the Investor Day to give a brief update.
是的。我的意思是,顯然很難針對具體個案評論,但就併購面而言,我們的案源(pipeline)持續不錯;不過老實說,我們未來 24 到 36 個月的有機成長機會看起來也相當有前景。我先從能源這件事以及脈衝功率特種薄膜產品線之外的部分談起。還有幾件我們在投資人日提過的事情,我簡單更新一下。
First, on our micro solutions within MSA. That's where we are taking our existing technologies, our existing capacity, our existing R&D capability. That we use for our hearing health and putting that into other medical applications. I would say I'm incrementally more positive about this than I was, say, two quarters ago. We got a lot of new medical applications where we're collecting NREs at this moment that we should start ramping into higher volume production in 2027. I mean, it's not going to generate a ton of revenue this year.
第一個是我們在 MSA 之內的微型解決方案(micro solutions)。這是我們把既有技術、既有產能、既有研發能力,也就是原本用在聽力健康(hearing health)的那些能力,延伸到其他醫療應用。我會說,相較於例如兩個季度前,我現在對這塊是逐步更樂觀的。我們目前有很多新的醫療應用案正在收取 NRE(非重複性工程費用),並且應該會在 2027 年開始爬坡到更高量的量產。我的意思是,今年它不會帶來非常大量的營收。
But remember these MedTech designs are typically three- to five-year design windows and we're getting to the beginning of that three years in the 2027 year time frame when we started this, so that's pretty positive. Defense spending, I just sit there and I see you read it every day, we're well positioned with defense spending, with our RF and our capacitive products. I think that's more of a secular growth trend where we have some very differentiated products.
但請記得,這些 MedTech 設計通常有三到五年的設計導入窗口;而我們啟動這件事後,到 2027 年的時間點大致就是那三年窗口的起點,所以這是相當正面的。至於國防支出,我只是坐在那裡每天看新聞,你也每天都會看到;我們在國防支出方面具備很好的布局,包含我們的 RF(射頻)與電容式產品。我認為這更像是一個長期的結構性成長趨勢,而我們有一些非常差異化的產品。
And then lastly, I think we're doing some work in terms of ceramic caps. In terms of, doing what I would say in defense under munitions, we're doing some assembly work. There's a lot of good stuff going on here. And so I generally thinking, I think I've been pretty positive. We said our organic growth of 4% to 6%, our first year out of the gate, we're at 7%. I think we're pretty excited about, how we think about our organic growth opportunities over the next 24 to 36 months.
最後,我想我們也在陶瓷電容(ceramic caps)方面做一些工作。就國防領域而言,在我所說的彈藥(munitions)相關,我們正在做一些組裝工作。這裡有很多不錯的進展。所以整體來說,我想我一直都相當正面。我們說過有機成長 4% 到 6%,我們第一年一出場就做到 7%。我們對於未來 24 到 36 個月的有機成長機會如何布局,感到相當興奮。
Christopher Rolland - Analyst
Christopher Rolland - Analyst
Thank you so much guys. Congrats.
非常感謝各位。恭喜。
Operator
Operator
Anthony Stoss, Craig-Hallam.
Anthony Stoss,Craig-Hallam。
Anthony Stoss - Analyst
Anthony Stoss - Analyst
Hey, Jeff, John, and Sarah. First off, John, maybe I missed it. Gross margin guide for March. I think in the past you were thinking about 42%. You maybe just confirm that. And then I'm just curious what you think the June quarter gross margin might look like if the ramp is going to occur until late Q2, does that spill into the June quarter gross margins? Thanks.
嗨,Jeff、John 和 Sarah。首先,John,也許是我漏聽了。3 月的毛利率指引。我記得過去你們是以大約 42% 來思考。你能否確認一下。另外我也好奇,如果爬坡要到第二季後段才發生,那 6 月季度的毛利率可能會長什麼樣子?這會不會影響到 6 月季度的毛利率?謝謝。
John Anderson - Chief Financial Officer, Senior Vice President
John Anderson - Chief Financial Officer, Senior Vice President
Yeah. Tony, we really -- we kind of moved away as we transitioned to an industrial tech company. We kind of moved away from gross margin, so the guide, the focus on our guide is obvious revenue, EPS, and cash flow. I would say from -- if you give a little detail on gross margin, we're at, call it, full year 2025, we're at 45.5%. And MSA was, as I mentioned, above 50%.
是的。Tony,我們其實——隨著我們轉型成工業科技公司,我們某種程度上不再那麼強調毛利率。所以指引的重點很明確是營收、EPS(每股盈餘)以及現金流。如果稍微補充一些毛利率細節:以 2025 全年來看,我們大約是 45.5%。而 MSA 如我提到的,是在 50% 以上。
I think the MSA margins are going to kind of hold in that area in '26, but there is potential for margin expansion, especially in the back half of 2026, as we get to higher production volumes or ramped up production volumes on that specialty film line. So I think there -- again, there's an opportunity to increase above that 44.5% in '26 by, call it, 50 to 75 basis points, but weighted toward the back half of the year.
我認為 MSA 的毛利率在 2026 年大致會維持在那個水準,但仍有毛利率擴張的可能性,特別是在 2026 年下半年,當我們在特種薄膜產品線上達到更高的產量、或完成產量爬坡之後。所以我認為——再次強調——2026 年有機會在 44.5% 之上再提升,大約 50 到 75 個基點,但會偏向在下半年實現。
Anthony Stoss - Analyst
Anthony Stoss - Analyst
Got it. Thanks for that. And Jeff, I'm curious if you could kind of highlight the fastest growing markets or what you expect for 2026. I got to believe it's the military, and I'm curious if you have exposure on the satellite side as well.
了解。謝謝你的說明。另外 Jeff,我好奇你是否可以重點談一下 2026 年成長最快的市場,或你們對 2026 年的預期。我相信應該是軍事領域;我也想知道你們在衛星端是否也有曝險/布局。
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
We do have some exposure to satellite, but just a comment, I think, I mentioned on the prepared remarks, that we had a very strong PD and a very strong bookings quarter. And even with that, the book-to-bill was 1.06 even with that very strong shipment quarter.
我們確實有一些衛星相關的曝險/布局;不過我補充一下,我想我在事先準備的發言中提到,我們本季 PD(產品開發/設計導入)非常強,接單(bookings)也非常強。即便如此,在出貨非常強勁的這一季,出貨比(book-to-bill)仍然是 1.06。
And I think we're already through January. We had a very strong January bookings month as well. And it's pretty broad based. We tried to cut this up a number of different ways, in terms of, our key markets of being defense, med, industrial, then we put ED and energy together. All of them are looking pretty strong right now. The bookings have been strong in supporting that.
而且我們現在已經走過 1 月。我們 1 月的接單也非常強。而且這是相當廣泛的。我們嘗試用很多不同方式切分:以我們的關鍵市場來看,包括國防、醫療、工業,然後我們把 ED 和能源放在一起。目前看起來全部都相當強勁。接單的強度也在支撐這個判斷。
And so, I think from our perspective it's very broad based. And if I look OEM versus distribution, same thing. Both our OEM business and distribution business is doing very well. And so, I think to pick one out and sit there and go, this one's doing the best, I mean defense is doing well, but so is a MedTech. MedTech business is doing well. You know the energy story, and I think the one that we're seeing more and more momentum is energy -- sorry, industrial. We're seeing more momentum in industrial than we did six months ago. So I think that that seems to be a pretty big positive change since the last six months.
所以從我們的角度來看,這是非常廣泛的成長。如果我看 OEM 相對於經銷/通路,也是同樣的情況。我們的 OEM 業務與通路業務都表現得非常好。因此要挑出某一個並說「這個最好」,其實很難;國防確實做得很好,但 MedTech 也很好。MedTech 業務表現也很好。你知道能源的故事;而我認為我們看到越來越多動能的是能源——抱歉,是工業。相較於六個月前,我們在工業端看到更多動能。所以我認為,這似乎是過去六個月以來一個相當大的正向變化。
Anthony Stoss - Analyst
Anthony Stoss - Analyst
Perfect. Congrats. Nice execution.
完美。恭喜。執行得很好。
Operator
Operator
Robert Labick, CJS Securities.
Robert Labick,CJS Securities。
Unidentified Participant
Unidentified Participant
Hey, this is Will on for Bob. I know you talked about the timeline of the energy orders, but can you talk more specifically about the production build out? Has the new capacity been completed, tested? Where does it stand?
嗨,我是 Will,代替 Bob 發問。我知道你們談過能源訂單的時程,但能否更具體談談產能擴建的進度?新產能是否已完成、測試?目前進展到哪一步?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Yeah. So I mean, we have weekly calls with the team. This is obviously happening in outside of Greenville, South Carolina. And so we have weekly calls. It's like every week there's something new, a couple weeks ago we got the permits to start producing product in the facility. The equipment's being moved in. We've got a team actually, in Greenville, from all over the world to help support this ramp up. We're bringing in manufacturing engineering team from across the globe and to help with the ramp up.
是的。我們每週都會和團隊開會。這項作業顯然是在南卡羅來納州格林維爾市郊外進行。所以我們每週都有電話會議。幾乎每週都有新進展;幾週前我們拿到了許可,可以在該廠開始生產產品。設備正在搬入。我們也有一支團隊實際在格林維爾,從世界各地來支援這次爬坡。我們正從全球各地調入製造工程團隊來協助爬坡。
So there's a lot going on plus at the same time we're still delivering, low volume units on this order, but you know the goal here is we're going to ramp this up like 10x in the next five months from where we are today. So I think we're on track, a lot to be done here, but we're on track in order to get it by the end of Q2.
所以目前事情很多;同時我們仍在交付這筆訂單的低量單位,但目標是在未來五個月內把目前的產量提升約 10 倍。因此我認為我們進度在軌道上,雖然還有很多要做,但我們有望在第二季末前達成。
The full volume production that we committed to. And again I think you know it depends on a lot about on auto orders and the rest of the specialty film business, exactly what we deliver on this energy order. But I think we're thinking in that, $50million to $65 million range from in the 20s, this year for 2025.
也就是我們承諾的滿載量產。再者,我想這也取決於汽車訂單以及其他特種薄膜業務的情況,進而影響我們在這筆能源訂單上實際交付多少。但我們的想法是,2025 年這筆訂單的規模大概會落在 5,000 萬到 6,500 萬美元區間(今年則是 2,000 多萬美元)。
John Anderson - Chief Financial Officer, Senior Vice President
John Anderson - Chief Financial Officer, Senior Vice President
And I will say, very modest amount in Q1. So it will help drive sequential growth from Q1 to Q2 as we ramp up.
我也要說,第一季的金額會非常小。因此隨著我們爬坡,將有助於帶動第二季相較第一季的季增。
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Yeah. So I think that's a good point. I think, obviously we're guiding to pretty decent organic growth year over year but that's not really being driven by the energy order obviously.
是的。我覺得這點說得很好。我想很明顯,我們對全年有相當不錯的有機成長指引,但那並不是主要由能源訂單所帶動。
Unidentified Participant
Unidentified Participant
That's very helpful. Thank you. And can you remind us, can that capacity be used for other pulse power applications beyond the energy order if the demand arises?
非常有幫助,謝謝。另外能否提醒一下:如果未來需求出現,這些產能是否也能用於能源訂單以外的其他脈衝功率(pulse power)應用?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Yeah. I mean like how we're setting this up, quite frankly is we're setting it up probably in the same facility but a little separated because the normal specialty line is much higher mix. This is essentially a low mix production and we're working on a lot of things that you will make the standard specialty film line more productive over time too like automation, we're doing a lot of things that will help longer-term with the standard specialty film line. But we're setting them up right next to each other as opposed to trying to build one high volume customer against more like I call higher mix customers.
可以。坦白說,我們的規劃是大概在同一個廠房內,但會稍微分隔,因為一般的特種產線是高混合(high mix)。而這條基本上是低混合(low mix)生產;我們也在推動許多事項,未來也會讓標準特種薄膜產線更具生產力,例如自動化等,我們做的很多事情長期都會幫助標準特種薄膜產線。但我們會把它們設在彼此相鄰,而不是試圖用一條線去同時服務一個高量客戶與我所說的高混合客戶。
Unidentified Participant
Unidentified Participant
That's all for me, thank you.
我這邊就這些,謝謝。
Operator
Operator
(Operator Instructions) Tristan Gerra, Baird.
(接線員指示) Tristan Gerra,Baird。
Tyler Bomba - Analyst
Tyler Bomba - Analyst
Hi, this is Tyler Bomba on for Tristan. Thanks for taking the questions. You touched on it briefly already, but could you give us a more detailed update on the supply demand dynamics and industrial? Do you expect the second half to see industrial revenue rebounding if the first half is kind of back to supply and demand balance?
嗨,我是 Tyler Bomba,代替 Tristan 發問。謝謝讓我提問。你剛才已稍微提到,但能否更詳細更新一下工業領域的供需動態?如果上半年大致回到供需平衡,你是否預期下半年工業營收會回升?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Yeah. So when I look at like our numbers in our forecast here, I think, we expect in the first half right now, we expect pretty strong industrial shipments in the first half of what was pretty strong in the back half of 2025. And then I would sit there and say right now the back half of the year looks more right now it looks more flattish to the back half of 2025 industrial, for industrial specifically. But overall we expect growth for industrial for the full year.
是的。就我們目前的數字與預測來看,我們預期上半年工業出貨會相當強勁,延續 2025 年下半年的強勢表現。而就目前而言,今年下半年看起來相較 2025 年下半年(就工業而言)會比較持平。但整體來說,我們仍預期工業全年會成長。
So like obviously if you go back to, Tyler to when we were talking earlier last year, the first half in industrial of 2025 was still relatively meagerly weak. We're seeing a fair amount of growth in the first half of 2026. And then I think, it's a little early. Industrial is a lot more turns business. The lead times are shorter, but right now, I think what I see here is we're going to be flattish year over year in the back half.
Tyler,如果回到我們去年較早時的討論,2025 年上半年工業端其實仍相對偏弱。我們看到 2026 年上半年有相當幅度的成長。然後我想現在還有點早。工業業務的周轉(turns)特性更強。交期較短,但就目前我看到的情況,下半年同比會比較持平。
Tyler Bomba - Analyst
Tyler Bomba - Analyst
It's very helpful. A quick follow-up. We're starting to hear about shortages of components across the industry. Is this impacting your demand and are the supply constraints expected to possibly impact price in the second half?
非常有幫助。我有個簡短追問。我們開始聽到整個產業出現零組件短缺。這是否影響你們的需求?供應限制是否可能在下半年影響價格?
Jeffrey Niew - President, Chief Executive Officer, Director
Jeffrey Niew - President, Chief Executive Officer, Director
Well, I mean, we're always looking at price, Tyler. So I think you're absolutely right. I mean, there's a number of things here that dynamics that I think are going on and we continue to see. I mean, like I said, in the previous question, with the book-to-bill, when we were having these strong book-to-bills in the front half of '25. It was off of weak shipments, so you could -- you got to take that book-to-bill with a grain of salt.
嗯,我們一直都在關注價格,Tyler。所以我認為你說得完全正確。這裡有不少動態因素正在發生,而且我們也持續看到。就像我在前一題提到的,當我們在 2025 年上半年看到很強的接單出貨比(book-to-bill)時,那是建立在出貨偏弱的基礎上,所以——你得對那個接單出貨比保留一些解讀空間。
But when you look at the Q4 numbers in terms of the revenue being $90 million and you still look at a book-to-bill 1.06. And I said, January is already in the books and the bookings in January were already strong again. And so it's definitely a topic here about capacity utilization, pricing, all intermixed.
但如果你看第四季的數字,營收是 9,000 萬美元,同時接單出貨比仍有 1.06。而且我也說過,一月已經結束,一月的接單也再次很強。因此產能利用率、定價等議題,確實是交織在一起的討論重點。
And to be honest with you I would sit there and say we are starting to see some concerns as we enter towards the back half of the year that we got to make sure we're prepared for all the orders we're receiving. So I think if this demand continues at this rate.
坦白說,隨著我們進入下半年,我會說我們開始看到一些疑慮:我們必須確保已為收到的所有訂單做好準備。所以如果需求以這樣的速度持續下去的話。
Tyler Bomba - Analyst
Tyler Bomba - Analyst
Great, that's all for me, thanks. Great.
很好,我這邊就這些,謝謝。很好。
Operator
Operator
And everyone at this time there are no further questions. That does conclude our conference for today. We would like to thank you all for your participation. You may now disconnect.
各位,目前沒有其他問題。今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。